A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Conditions:   Esophageal Cancer;   Oesophageal Cancer;   Oesophageal Cancer Metastatic;   Esophageal Cancer Metastatic;   Esophageal Cancers NOS;   Oesophageal Cancer Nos;   GastroEsophageal Cancer;   Gastrooesophageal Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
Sponsors:   AIO-Studien-gGmbH;   Bristol-Myers Squibb
Not yet recruiting

from #ORL via a.lsfakia on Inoreader http://ift.tt/2BGvORh
via IFTTT